ライフサイエンスコーパス: infinity

1 -1-ene-1,4-diyl] nitrogen chains [-N-N-N=N-](infinity) .

2 ailure was -0.007 (1-sided 95% CI, -0.036 to infinity).

3 NH3)2PbI4 (n = 1) to 1.52 eV CH3NH3PbI3 (n = infinity).

4 tus (P < 0.05; OR, infinity; 95% CI, 0.76 to infinity).

5 ds ratio, 19.6; 95% confidence interval, 2.9-infinity).

6 ratio, 8.5; 95% confidence interval, 1.3 to infinity).

7 outcome from ketamine was 25 (95% CI, six to infinity).

8 cocaine concentration in brain, and the AUC2(infinity).

9 , SS, or SZ genotypes was 14.58 (95% CI 2.33-infinity).

10 fidence interval for half-life, 11 months to infinity).

11 when the system's carrying capacity tends to infinity).

12 (5; 95% CI, 3-9) than PCR-CI (27; 95% CI, 12-infinity).

13 c reference frames by placing visual cues at infinity.

14 ht V are perfectly transmitted even as V --> infinity.

15 ency distributions ranging from alpha = 2 to infinity.

16 divergent, almost everywhere either zero or infinity.

17 well as a positron component that escapes to infinity.

18 under selection and migration forces as t-->infinity.

19 imension of [Formula: see text] increases to infinity.

20 lly with speed c(*) in the population as t-->infinity.

21 reduction of the NPA, specified from optical infinity.

22 s the number of bases in each genome goes to infinity.

23 generally become unbounded as time tends to infinity.

24 the x-axis, represents all K values, zero to infinity.

25 the sense that Sigmainfinityn=1 dist(dn, X)<infinity.

26 radiation, which propagates toward quiescent infinity.

27 r operators with magnetic tensors growing at infinity.

28 perators with electric potentials growing at infinity.

29 , S(BG)(N) proportional, variant N for N --> infinity.

30 in the limit as the number of demes tends to infinity.

31 s 100% as the seal/membrane ratio approaches infinity.

32 limiting cases of alpha --> 0 and alpha --> infinity.

33 onant scattering, when wavelength approaches infinity.

34 onal Naming Game corresponds to setting w at infinity.

35 pe fractionation only, leading to LambdaC/Br infinity.

36 s rapidly achieved by increasing alphaA/d to infinity.

37 control subjects (OR = infinity [95% CI 1.2-infinity]).

38 adjusted RR, 0.98 [97.5% 1-sided CI, 0.92 to infinity]).

39 difference, 0.1% [1-sided 97.5% CI, -4.4% to infinity]).

40 0(-4); odds ratio (OR) = 11.3, 95% CI = 3.7, infinity].

41 ., S(q)(N) proportional, variant N for N --> infinity].

42 such that Lambda(T = 0) = 1 and Lambda(T --> infinity) = 0.

43 uted from size at age data were 4.48 m for L(infinity), 0.219 y(-1)for k, and -0.81 y for t(0).

44 ed 95% CI for treatment-end difference was (-infinity, 0.07) HAM-D points, indicating a non-inferiori

45 raction (Cmax, 0.00; AUC0-96, 0.54; and AUC0-infinity, 0.36; P >/= .76).

46 tions lead to the polymeric [[Ag(bptz)][PF6]]infinity (1) and the dinuclear compounds [Ag2(bptz)2(CH3

47 t(2)O yields [(Et(2)O)(3)Ln[Co(4)(CO)(11)]]( infinity ) (1, Ln = Yb; 2, Ln = Eu).

48 2)O)(3)(-)(x)()(THF)(x)()Ln[Co(4)(CO)(11)]]( infinity ) (1-3) possesses pseudo C(3)(v)() symmetry (an

49 2)O)(3)(-)(x)()(THF)(x)()Ln[Co(4)(CO)(11)]]( infinity ) (1-3; x = 0, 1) and [(THF)(5)Eu[Co(4)(CO)(11)

50 th a positive likelihood ratio approximating infinity [1/0 (--> infinity)], and with a negative likel

51 and reaction-limited (k(R)) rates, i.e., 1/k(infinity) = 1/k(D) + 1/k(R).

52 in which oxide ions in Sr(n+1)V(n)O(3n+1) (n=infinity, 1, 2) phases are topochemically replaced by hy

53 n change in FEV1 was 7.0% (97.5% CI, 3.4% to infinity; 1-sided P < .001), and the between-group St Ge

54 of 14.6 m (Hodges-Lehmann 97.5% CI, 0.4 m to infinity; 1-sided P = .02).

55 fference, -4.8% [1-sided 95% CI, -13.6% to + infinity; 1-sided P = .19]) and 49 (66%) vs 58 (62%), re

56 difference, 4.7% [1-sided 95% CI, -7.0% to + infinity; 1-sided P = .25).

57 n-group difference, 11.8% [97.5% CI, 1.0% to infinity]; 1-sided P = .01).

58 infinity) = 48 +/- 35 Pa for Jurkat cells, E(infinity) = 156 +/- 87 for neutrophils, mean +/- SD).

59 significantly with dose (rifapentine AUC(0- infinity): 296, 410, and 477 microg.hour/ml at 600, 900,

60 affords [(Et(2)O)(2)(THF)Yb[Co(4)(CO)(11)]]( infinity ) (3) and [(THF)(5)Eu[Co(4)(CO)(11)]]( infinity

61 he novel imidazolate metal-organic framework infinity(3)[Ba(Im)2] with divalent europium.

62 was (1-2 prescriptions, HR = 0 [95% CI, 0.00-infinity]; 30-39 prescriptions: HR = 3.23, 95% CI, 1.26-

63 In contrast, [(THF)(5)Eu[Co(4)(CO)(11)]]( infinity ) (4) incorporates a C(2)(v)() symmetric cluste

64 ; x = 0, 1) and [(THF)(5)Eu[Co(4)(CO)(11)]]( infinity ) (4), were prepared and structurally character

65 inity ) (3) and [(THF)(5)Eu[Co(4)(CO)(11)]]( infinity ) (4).

66 riables: AUC0-96, 2.58; Cmax, 0.64; and AUC0-infinity, 4.05; P >/= .13) and that the 3 products were

67 infinity) = 855 +/- 670 Pa for HL60 cells, E(infinity) = 48 +/- 35 Pa for Jurkat cells, E(infinity) =

68 Strep A assay, performed using the GeneXpert Infinity-48s.

69 eak power-law dependence on pulling speed, f(infinity) = 60 pN(nu(pull)/microm/s)(0.25).

70 absolute difference, -3.7%; 95% CI, -9.1% to infinity); 78 patients (26.9%) in the high-flow group vs

71 and suicide deaths (OR, 15.62; 95% CI, 1.65-infinity [8 cases and 39 controls]).

72 er the plasma-concentration time curve [AUC0-infinity), 81.6+/-22.0 microg.min/mL; n=6) were not sign

73 stiffer than human neutrophils on average (E(infinity) = 855 +/- 670 Pa for HL60 cells, E(infinity) =

74 during labor (T(1/2), 87.3+/-24.7 min; AUC0-infinity, 88.1+/-16.6 microg.min/mL; n=6).

75 ts but were absent in control subjects (OR = infinity [95% CI 1.2-infinity]).

76 OR = 4.52, 95% CI: 2.00, 10.20) and E6 (OR = infinity, 95% CI: 4.64, infinity) of HPV16, as well as l

77 indefinitely among HIV- subjects (half-life; infinity, 95%CI, 309 years-infinity) but declined rapidl

78 64), and cagA-positive status (P < 0.05; OR, infinity; 95% CI, 0.76 to infinity).

79 t 10q11.21q11.23: 5 [0.2%] vs 0 [0.03%]; OR, infinity; 95% CI, 1.26-infinity; corrected P = .71).

80 ree during year 2 of follow-up (odds ratio = infinity; 95% CI, 11.8 to infinity; P < .001).

81 mong HIV-uninfected participants (half-life, infinity; 95% confidence interval, 309 years to infinity

82 the concentration-time curve from time 0 to infinity after single dosing (AUC(inf) ) and maximum obs

83 tric field dependence goes to 0 as r goes to infinity and 1/r goes to 0, the molecular shielding cons

84 These spacetimes are analytic about infinity and contain a dimensionless coupling constant M

85 nd m=3 for compound 2 (after 10 days), and n=infinity and m=5 for compound 3 (after 14 days).

86 ul toward a systematic approach to bypassing infinity and thus going beyond it in a broader range of

87 ance, and -13.4 points (95% CI, -8 points to infinity) and -10.6 points (95% CI, -5.8 points to infin

88 (1-sided 95% CIs) of 2.6% (95% CI, -8.9% to infinity) and -3.6% (95% CI, -15.5% to infinity), respec

89 ant (matched odds ratio, 4.6; 95% CI, 2.1 to infinity) and eating pico de gallo salsa (matched odds r

90 rebound was 0.107 (1-sided 95% CI, 0.028 to infinity) and for viral failure was -0.007 (1-sided 95%

91 tate activation and inactivation functions m(infinity) and h(infinity), as Boltzmann curves, defined

92 Experimental values of ST(m)/ST(m, infinity) and its dependence on /Z/ are in good agreemen

93 = I, Br; n = number of layers = 1, 2, 3 ... infinity) and reversibly tune the dimensionality (n) by

94 ver time t(cross), and the limits D(0) and D(infinity) and to relate these quantities to the escape t

95 Si, [(CH(3))(2)Ge](infinity), [(CH(3))(2)Sn](infinity), and [(CH(3))(2)Pb](infinity) is offered in te

96 ihood ratio approximating infinity [1/0 (--> infinity)], and with a negative likelihood ratio equal t

97 L; sensitivity, 64%; specificity, 100%; PLR, infinity; and NPR, 0.36).

98 ul (positive likelihood ratio 213 [95% CI 13-infinity] and negative likelihood ratio 0.11 [0.04-0.32]

99 ental analysis (AUC from 0 to infinity [AUC0-infinity] and to the next dose [AUC0-tau]), and by indiv

100 ifference, -1.6% [1-sided 97.5% CI, -6.3% to infinity]) and 89.7% and 93.6%, respectively, in the cli

101 g octahedral lead bromide chains [PbBr4 (2-)]infinity are surrounded by the organic cations C4N2H14 (

102 erns of different members (m = 0, 6, 12, 18, infinity) are consistent with pure phases crystallizing

103 ve hole mass, which ranges from near zero to infinity as a function of conformation, is used as a mea

104 a "Hall-insulator" phase in which rhoxx --> infinity as T --> 0 whereas rhoxy approaches a nonzero v

105 and inactivation functions m(infinity) and h(infinity), as Boltzmann curves, defined by half-activati

106 oarsenates have infinite single chains of (1/infinity)[AsQ(2)(-)] derived from corner-sharing pyramid

107 have polar structures built of different (1/infinity)[AsSe(2)(-)] chain conformations, whereas the d

108 75 mg/m2/d; the mean +/- SD C(max) and AUC(0-infinity) at 10 mg/m2/d were 776 +/- 459 nM and 1,355 +/

109 (1-sided 95% CIs) of 10.6% (95% CI, -1.2% to infinity) at the 0.6-mg/kg dose; 9.9% (95% CI, -0.9% to

110 t the 0.6-mg/kg dose; 9.9% (95% CI, -0.9% to infinity) at the 1.2-mg/kg dose, and 8.4% (95% CI, -2.6

111 he 1.2-mg/kg dose, and 8.4% (95% CI, -2.6 to infinity) at the 1.8-mg/kg dose.

112 e very fast, i.e., red = ox + nETe(-) (kox = infinity) at the OE and ox + nETe(-) = red (kred = infin

113 ty) at the OE and ox + nETe(-) = red (kred = infinity) at the RE.

114 r laws that would diverge (that is, approach infinity) at ~225 K, so there may be a link between wate

115 ifference, -3.9% [1-sided 97.5% CI, -8.2% to infinity]) at test of cure.

116 he plasma concentration time curve from 0 to infinity (AUC(0-infinity)) of S-warfarin increased by 57

117 sma concentration-time curve extrapolated to infinity (AUC(0-infinity)) was 900 ng.h/mL, which is sim

118 asma concentration-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72,

119 ), non-compartmental analysis (AUC from 0 to infinity [AUC0-infinity] and to the next dose [AUC0-tau]

120 ntains 1D, hydrogen-bonded NH(4) (+) ...(1) (infinity) [B(SO(4) )(4/2) ](-) chains.

121 ordination network {[Fe(bbtr)(3)](BF(4))(2)}(infinity), bbtr = 1,4-di(1,2,3-triazol-1-yl)butane, the

122 tent with the interesting shear behavior and infinity bulk modulus of the same pattern.

123 d for bandgap tuning from E g = 1.60 eV (n = infinity; bulk) to 2.40 eV (n = 1).

124 jects (half-life; infinity, 95%CI, 309 years-infinity) but declined rapidly among HIV+ subjects (half

125 inity; 95% confidence interval, 309 years to infinity) but declined rapidly among HIV-infected partic

126 res characterized by their rate of growth at infinity, but if the growth is faster than a certain thr

127 y 4.6-fold and increased tacrolimus DN_AUC(0-infinity) by approximately 70-fold.

128 rine dose-normalized (DN) exposure (DN_AUC(0-infinity)) by approximately 4.6-fold and increased tacro

129 s, (ii) as z-score ranges from minus to plus infinity, calculating average scores can lead to canceli

130 The association rate constant (k(infinity)) can be decomposed into contributions from dif

131 ces [(CH(3))(2)](infinity)Si, [(CH(3))(2)Ge](infinity), [(CH(3))(2)Sn](infinity), and [(CH(3))(2)Pb](

132 - chain, whereas the analogous -(SeF4 -SeF4 )infinity - chain was found to have a number of imaginary

133 med the dynamic stability of the -(SF4 -SF4 )infinity - chain, whereas the analogous -(SeF4 -SeF4 )in

134 uestion in the context of robust control (H (infinity)-control), a control strategy that specifically

135 ure (risk difference, 12.9%; 95% CI, 6.6% to infinity) [corrected].

136 MS) that uses an infrared microscope with an infinity-corrected reflective objective and a continuous

137 2%] vs 0 [0.03%]; OR, infinity; 95% CI, 1.26-infinity; corrected P = .71).

138 ized the g(V) curve but hyperpolarized the h(infinity) curve.

139 ensemble-state estimates explode to machine infinity, despite the true state remaining in a bounded

140 agents, and the association rate constant k(infinity) determined from both contributions has a quali

141 ve a focal length ranging from -infinity to +infinity (divergent and convergent), are also readily in

142 ion where the optical path length approaches infinity due to the Poynting vector lying nearly paralle

143 cle spacings that otherwise would diverge to infinity due to viscous disturbance flows.

144 reagents over a wide Si/Al range from 15 to infinity, enabling the catalyst acidity to be tailored t

145 precise interface control--from just the n = infinity end members (perovskites) to the entire RP homo

146 of a letter target for 5 minutes at optical infinity, followed by 3 minutes of viewing the target at

147 tion and area under the curve from time 0 to infinity for colchicine plus CYP3A4/P-glycoprotein inhib

148 re within the range of 80-125% (GMR for AUC0-infinity for IVM, 87.9; DEC, 92.9; ALB-SOX, 100.0; and A

149 The GMR of Cmax, AUC0-t, and AUC0-infinity for IVM, DEC, ALB-SOX, and AZI were within the

150 ted in an invariant form; however, it gives +infinity for magnetic Schrodinger operators with magneti

151 brain abnormalities; and OR 24.7 (95% CI 2.9-infinity) for four cases without brain abnormalities.

152 all matched odds ratio was 73.1 (95% CI 13.0-infinity) for microcephaly and Zika virus infection afte

153 % CI, 4-37) for PFS and 119.5 mo (95% CI, 81-infinity) for OS (P < 10(-3)).

154 OS was 12 mo (3 mo to infinity) for patients with main PVT, versus 21.5 mo (12

155 zed patients versus 151 months (95% CI, 4 to infinity) for sensitized patients (P=0.5).

156 (95% CI 8.6-infinity); OR 113.3 (95% CI 14.5-infinity) for seven cases with brain abnormalities; and

157 ty) and -10.6 points (95% CI, -5.8 points to infinity) for St George's Respiratory Questionnaire (1-s

158 and TeO6 polyhedra, which form a [TeMg3P2O14]infinity framework.

159 Theory predicts an axially symmetric (D(infinity h)) structure and a triplet electronic ground s

160 erpreted in terms of an axially symmetric (D(infinity h)) structure.

161 e equivalent from secondary particles of LET(infinity)H(2)O >=15 keV/mum deposited within the plateau

162 tical and computational dynamic models reach infinity in finite time, extending analysis and numerics

163 n the presence of nZVI in anoxic conditions; infinity in the case of catalytic oxidation by H2O2 with

164 ately 1:1 in the SCN5A interdomain linker to infinity in the pore, transmembrane, and linker in KCNH2

165 (a limit such as the number of neurons N --> infinity, in which the fluctuations vanish) to the fluct

166 r the plasma concentration-time curve (AUC(0-infinity)) increased significantly with dose (rifapentin

167 mean-squared error M(rho;beta) = lim(M,N --> infinity)inf(lambda)sup(rank(X) </= rho . M)MSE(X,X(lamb

168 [(CH(3))(2)Sn](infinity), and [(CH(3))(2)Pb](infinity) is offered in terms of the simple Ladder C mod

169 with the same base composition (ST(m)/ST(m, infinity)) is independent of base composition but strong

170 can be in-situ tuned from near-zero to near-infinity kappa.

171 = 3 injury was 63 kph [39.1 mph (95% CI, 51-infinity kph)].

172 We prove that lim(n--> infinity )(log c(n)(Lambda)/((log n)(2)/log log n))=(3-2

173 tion stratification is 2.44 (95% CI 1.048 to infinity, Mantel-Haenszel test p=0.036).

174 easurable concentration, AUC extrapolated to infinity, maximum concentration [Cmax], and time to Cmax

175 tial Differential Equations, the crossing of infinity may persist for finite time, necessitating the

176 = 57.96, 95% confidence interval [CI]: 3.30-infinity, mean age no mutations = 50.35; p-value = 0.002

177 cked with SrH layers/chains, such that the n=infinity member, SrVO2H, can be considered to be analogo

178 mplete success and 30.3 months (95% CI, 19.0-infinity months) and 33.3 months (95% CI, 25.7-46.2 mont

179 months (95% confidence interval [CI], 15 to infinity months) with a 6-month PFS of 98% (95% CI, 94%

180 l [CI], 28.1-87.1) and 48.6 (95% CI, 25.5 to infinity) months, respectively (P = 0.828, log-rank test

181 1,..., bn) are arbitrary vectors in R(+)n=[0,infinity)n, and rho(mij) is the spectral radius of an n

182 hat, we consider two new methods, adaptive L(infinity)-norm penalized NSC (ALP-NSC) and adaptive hier

183 fferential Equation examples the crossing of infinity occurs instantaneously.

184 sipeptide concentration-time curve from 0 to infinity of 2,414 ng/mL/h, similar to adults.

185 on-time area under the curve (AUC) from 0 to infinity of 239.6 ng/mL x h.

186 octahedral one, and a systematic, countable infinity of icosahedral ones, one for each Goldberg tria

187 stinguish, remember and understand a virtual infinity of objects.

188 ures should visual neurons encode, given the infinity of real-world images and the limited number of

189 about unrealized possible actions - the vast infinity of things that were not (or have not yet been)

190 one-dimensional carbon nanotube and lateral infinity of two-dimensional graphene.

191 actions that are worth considering from the infinity of unrealized actions that are better left igno

192 10.20) and E6 (OR = infinity, 95% CI: 4.64, infinity) of HPV16, as well as low CD4+ cell counts, whe

193 tration time curve from 0 to infinity (AUC(0-infinity)) of S-warfarin increased by 57% (90% CI, 32% t

194 and not linked with higher rifapentine AUC(0-infinity) or peak concentration.

195 not affect the area under the curve (AUC(0-->infinity)) or the half-lives of sulfadoxine or pyrimetha

196 of pathogenic (95% confidence interval: 4.0-infinity), or an odds ratio of 9.9 for a prediction of b

197 infection; crude overall OR 55.5 (95% CI 8.6-infinity); OR 113.3 (95% CI 14.5-infinity) for seven cas

198 to 4.0]), BVAB2 (risk ratio, 8.7 [CI, 2.5 to infinity]), or BVAB3 (risk ratio, 3.1 [CI, 1.7 to 5.8]);

199 , and extrapolating to the bulk limit (N --> infinity), our analysis supports the assignment of the "

200 D ratios, were 1.0 (referent), 1.3, 5.0, and infinity (P for trend < 0.0001).

201 tion curve compared with pdVWF-pdFVIII (AUC0-infinity) (P < .01).

202 care groups were +0.09 L (95% CI, 0.05 L to infinity) (P = .001) and +0.08 L (95% CI, 0.03 L to infi

203 y) (P = .001) and +0.08 L (95% CI, 0.03 L to infinity) (P = .002) for forced expiratory volume in the

204 in the first second, +21 m (95% CI, -4 m to infinity) (P = .06) and +21 m (95% CI, -5 m to infinity)

205 finity) (P = .06) and +21 m (95% CI, -5 m to infinity) (P = .12) for 6-minute walk distance, and -13.

206 between groups of -27.0% (95% CI, -31.6% to infinity) (P = .89).

207 ed 97.5% confidence interval [CI], (-7.90 to infinity); P = 0.0666; and 97.5% CI, (-8.51 to infinity)

208 finity); P = 0.0666; and 97.5% CI, (-8.51 to infinity); P = 0.1178; for combination regimens vs. mono

209 8.8% difference (1-sided 97.5% CI, 0.009 to infinity; P < .001 for noninferiority).

210 difference of 7.2% (1-sided 95% CI, -3.0% to infinity; P < .001).

211 w-up (odds ratio = infinity; 95% CI, 11.8 to infinity; P < .001).

212 ratio = 22.84; 95% confidence interval, 3.57-infinity; P < .001).

213 73; P = .009 and MOR, 39.35; 95% CI, 7.85 to infinity; P < .001, respectively).

214 med >91 but <227 surgeries/year (95% CI, 169-infinity; P < 0.05) gained more letters than average.

215 ed >110 but <293 surgeries/year (95% CI, 232-infinity; P < 0.05) were approximately 15% more likely t

216 -group difference, -0.14; 97.5% CI, -3.07 to infinity; P = .001 for noninferiority), meeting criteria

217 ty (difference, -3%; 1-sided 95% CI, -10% to infinity; P = .004 for noninferiority).

218 , 0-27 days) (mean ratio, 1.04; 95% CI, 0.95-infinity; P = .007 for noninferiority), and the lower bo

219 oup difference of 18% (1-sided 95% CI, 4% to infinity; P = .03).

220 mab group (odds ratio, 3.28; 85% CI, 1.54 to infinity; P = .034).

221 ia (difference, -6%; 1-sided 95% CI, -20% to infinity; P = .14 for noninferiority).

222 n (26%) (difference, -1.6%; 95% CI, -0.15 to infinity; P = .66).

223 difference, -5.3%; 1-sided 95% CI, -10.8% to infinity; P for noninferiority = .41).

224 clophosphamide (odds ratio 110, 95% CI 14.04-infinity; p=0.00001).

225 onth follow-up by 42.6 m ([90% CI, +22.2 to +infinity] P=0.005) at 2.5 hours after a final study beve

226 dy beverage and by 18.0 m ([90% CI, -1.7 to +infinity] P=0.12) at 24 hours after a study beverage, co

227 een-group difference, 0.03 [95% CI, -0.07 to infinity], P < .001), meeting the prespecified margin of

228 difference of -0.3% [1-sided 95% CI, -4% to infinity]; P < .001 for noninferiority).

229 MT group (difference, 4.7% [95% CI, -5.2% to infinity]; P < .001 for noninferiority).

230 group (difference, -1.6% [95% CI, -10.5% to infinity]; P = .01 for noninferiority).

231 (risk difference of -7.0% [95% CI, -12.4% to infinity]; P = .38 for noninferiority).

232 1% (71.8% vs 67.7%; [1-sided 95% CI, -4.6 to infinity]; P value for noninferiority = .002) at week 12

233 4% (63.9% vs 64.3%; [1-sided 95% CI, -6.9 to infinity]; P value for noninferiority = .004) at week 1,

234 7% (66.8% vs 67.6%; [1-sided 95% CI, -8.1 to infinity]; P value for noninferiority = .01) at week 4,

235 difference, -3.5% [1-sided 95% CI, -11.5% to infinity]; P value for noninferiority = .06).

236 parallel one-dimensional helical chains of 1/infinity[P2Se62-] which depict an oxidative polymerizati

237 hear force was obtained as [0, 0.20] [0.35, +infinity] Pa.

238 pport vector machine with L(1) and joint L(1,infinity) penalties for binary and multiclass classifica

239 AA-related mortality and $7600 (CI, $3300 to infinity) per life-year gained based on all-cause death.

240 ligomer embedded in polymeric DNA (Deltan(u, infinity), per charge).

241 h a positive amyloid scan developed AD (OR = infinity; PPV = 86%, 95% CI = 72-95; NPV = 100%, 95% CI

242 correlated with the standardised method AUC0-infinity (r(2)=0.74), but the latter correlated poorly w

243 We interpret these ST(m)/ST(m, infinity) ratios in terms of the ratio of thermodynamic

244 curve (AUC) value in brain (denoted by AUC2(infinity)) required to produce physiological effects has

245 ed to assign parameters X and [theta](lambda,infinity), required for rigorous calculation of FH value

246 9% to infinity) and -3.6% (95% CI, -15.5% to infinity), respectively.

247 e S0 and Sinfinity are [S] at time t = 0 and infinity, respectively, gives access to ki under any con

248 tic metamaterials with Poisson ratio -1 and -infinity, respectively.

249 l limits ranged from 4.0 to 10.0, and 6.0 to infinity, respectively.

250 the penetration depth is predicted to go to infinity, resulting in zero mass, consistent with our me

251 for making COFs with valency 8 (cubes) and "infinity" (rods).

252 e formation of a cyclic bis[2]catenane with "infinity"-shaped topology via a 14-component self-assemb

253 The formation of Infinity-shaped construction leads to the development of

254 he surface of electrode and generation of an Infinity-shaped DNA structure in the absence of target b

255 Subsequently, no Infinity-shaped structure is formed following the introd

256 inite saturated regular helices [(CH(3))(2)](infinity)Si, [(CH(3))(2)Ge](infinity), [(CH(3))(2)Sn](in

257 red magnetic sublattices built of [FenSe4n+2]infinity single-chain edge-sharing octahedra, coherently

258 alysis of the dynamically stable -(SF4 -SF4 )infinity - structure revealed a multicenter character of

259 as [O(2)] --> 0 to 1.0 +/- 0.2 as [O(2)] --> infinity suggesting the dissociation rate constant from

260 m, and our observation of a lemniscate-type (infinity) supramolecular configuration clearly reveals a

261 benefit rises with the square of time (gain infinity t(1.94), R2=0.998, P<0.001).

262 All compounds contain the same parallel (1)/(infinity)[Ta(2)AsS(11)(3-)] polymeric anionic chains, bu

263 tly more total NER when extrapolating to t-->infinity than the other compounds studied.

264 f 119.5 mo (95% confidence interval [CI], 72-infinity), than for patients with a positive (18)F-FDG P

265 incide or asymptotically approach (for N --> infinity) the joint probabilities of the (N - 1)-system.

266 Then, when r --> infinity, the asymptotic lower density of the sequence o

267 s--is exact when the spatial dimension d --> infinity, the evolution of systems properties with d may

268 ies associated with black holes and includes infinity, thereby avoiding the need to impose radiative

269 n polymeric structure of [NaMn(II)(acac)(3)](infinity), through a series of elaborate design procedur

270 difference 0.05; stratified 95% CI, -0.18 to infinity), thus establishing noninferiority of omitting

271 32 generations), estimates of Ne ranged from infinity to <0.1% of the true value (defined as Ne based

272 which can have a focal length ranging from -infinity to +infinity (divergent and convergent), are al

273 .22 to 0.52]; difference, -37 days [95% CI, -infinity to -19.5]), but there was no significant effect

274 6.7% vs 25.0%; difference, -8.3%; 97.5% CI, -infinity to -2.0%; P < .001 for inferiority and P = .006

275 naire score improved -8.9 points (97.5% CI, -infinity to -6.3 points; 1-sided P < .001), each favorin

276 .06 (1-tailed 95% confidence interval [CI], -infinity to 0.27), our results demonstrate noninferiorit

277 itate group (ratio, 0.96 [1-sided 97.5% CI, -infinity to 1.09; P < .001 for noninferiority] [2-sided

278 P vs 14-day group, -3.1% [1-sided 97.5% CI, -infinity to 1.1]; P < .001; difference in 7-day vs 14-da

279 e hazard ratio was 0.97, 1-sided 97.5% CI = -infinity to 1.44, p = 0.44.

280 17.8%) (difference, 5.1% [1-sided 97.5% CI, -infinity to 16.3%]; 1-sided P = .19) became community am

281 , for a difference of 1.3% (1-sided 95% CI, -infinity to 3.05%, P = .06 for noninferiority).

282 ay vs 14-day group, 1.1% [1-sided 97.5% CI, -infinity to 6.3]; P < .001).

283 sual care (odds ratio, 1.8 [97.5% CI, 1.1 to infinity]; unadjusted between-group difference, 11.8% [9

284 ivariate stepwise regression analyses, AUC(0-infinity) values for rifapentine and the active 25-desac

285 ion (C(max)) and area under the curve (AUC(0-infinity)) values increased in a dose-proportionate mann

286 ver, dendritic growth and virtually relative infinity volume change during long-term cycling often le

287 under the concentration time curve from 0 to infinity was lower for the NM phenotype as compared to t

288 48 vs 256 h; P<.001), and the median AUC(0-->infinity) was ~40% lower (22,816 vs 40,106 microg/mL/h,

289 n-time curve extrapolated to infinity (AUC(0-infinity)) was 900 ng.h/mL, which is similar to adults r

290 From NLPB values of Deltan(u)/Deltan(u, infinity), we predict Delta as a function of [salt] and

291 mit, in which the population size approaches infinity, we demonstrate that, when multiple loci are co

292 on-time curve from time 0 to infinity (AUC(0-infinity)) were 162 +/- 155, 171 +/- 72, 182 +/- 157, an

293 G (T4; OR = 5), and T3197C+A12308G (U5; OR = infinity), were all strongly associated with AMD.

294 malized feedback current, I(T)(L) = i(T)/i(T,infinity), where L = d/a and d is the distance traveled

295 h a recent exact replica computation for d = infinity, whereas some observations differ, as rationali

296 (>or=10%) difference between ST(m) and ST(m, infinity) which increases strongly with decreasing lengt

297 ifference of -4.8% (1-sided 97.5% CI, -9% to infinity), which did not meet criteria for noninferiorit

298 otope slopes (Deltadelta13C/Deltadelta37Cl): infinity with PS, 0.33 +/- 0.04 for HY/DH and 1.5 +/- 0.

299 mations, it may become possible to go beyond infinity with the solution becoming again well behaved a

300 ool vary considerably among data sets at t-->infinity, with no clear dominance between (ii) and (iii)